The global cerebrospinal fluid management devices market size was valued at USD 2,750.20 million in 2022. It is projected to reach USD 4,548.70 million by 2031, growing at a CAGR of 5.75% during the forecast period (2023-2031).
Cerebrospinal fluid (CSF) is a body fluid found in the brain and spinal cord that protects the brain mechanically and immunologically. Diverse management devices, such as CSF shunts and CSF drainage systems, control the CSF flow away from the ventricles, thereby preventing the abnormal accumulation of CSF and hydrocephalus. The increasing prevalence of neurological disorders, increasing geriatric population, high demand for minimally invasive surgeries, rising disposable incomes, development of healthcare infrastructure, and development of advanced devices are the major factors driving the cerebrospinal fluid (CSF) management devices market. For the makers of cerebrospinal fluid management devices, new opportunities have arisen due to strategic acquisition, product innovation, and ongoing industry research and development (R&D). The rapidly advancing technological capabilities of these devices and the expansive scope of their applications in treating neurological illnesses have contributed to an increase in demand and spurred market expansion.
When a cerebrospinal fluid (CSF) builds up abnormally inside the brain's ventricles, which are hollow spaces, the condition is known as hydrocephalus. Young, middle-aged, and elderly individuals are all susceptible to developing hydrocephalus, as are infants and older children. For instance, the Hydrocephalus Association reports over 1,000,000 persons living with hydrocephalus in the U.S. In most cases, the surgical treatment known as ventriculoperitoneal (VP) shunting is used to treat hydrocephalus. With the help of a VP shunt, the patient's brain can be relieved of extra cerebrospinal fluid (CSF), and its flow and absorption are returned to normal.
According to statistics from the Pediatric Neurosurgery magazine, there are over 69,000 discharges each year in the US alone with a diagnosis of hydrocephalus. A shunt is implanted in 33,000 of these visits' almost 36,000 shunt-related procedures. As a result, the prevalence of hydrocephalus is rising, which prompts an increase in shunting procedures, which drives the expansion of the global market for cerebrospinal fluid management devices.
Shunting successfully lowers the pressure in the brains of individuals with neurological illnesses. Shunt systems need to be checked on and followed up on frequently. While performing the shunting technique, difficulties can arise. Mechanical failure, blockages, and infections are some complications that can happen with shunt systems. Severe effects from shunt dysfunction can include excessive or insufficient CSF drainage. In turn, this may result in the collapse of the ventricles, which can then result in migraines or a brain hemorrhage. CSF shunt system issues may therefore hamper market development.
Due to their underdeveloped research and development sectors and inability to handle emerging health concerns, developing nations represent an opportunity for several businesses. Africa depends on imported drugs and other medical equipment while having a high demand for them. Although Africa has significant treatment needs, the healthcare sector is growing slowly due to the continent's poor economic conditions. Furthermore, neurological illnesses have a substantial patient population in emerging economies like Brazil, Russia, and China. It is anticipated that the presence of such a sizable patient base in this area and rising healthcare costs will present opportunities for market participants for CSF management devices.
The global cerebrospinal fluid management devices market is segmented by product, age group, and end-user industry.
Based on product, the global cerebrospinal fluid management devices market is bifurcated into shunts, critical care products, dural sealants, and others.
The dural sealants segment is the major contributor to the market and is estimated to grow at a CAGR of 5.65% during the forecast period. Dural sealants improve the watertight dural closure, lowering the likelihood of CSF leaking during cranial procedures. It comes in various forms, including patches, hydrogel, and auto spray. It also helps decrease blood loss, lower the risk of surgical site infections, and mends injured tissues. However, compared to suturing alone, dural sealants are less efficient at preventing postoperative CSF leakage. The category is anticipated to expand during the forecast period due to increased CSF procedures.
Additional categories for critical care products include external drainage systems and accessories. The CSF is transferred from the valve to the peritoneal cavity, heart, or other drainage locations using the external drainage systems, which consist of an outflow catheter that goes beneath the skin. External Ventricular Drainage (EVD) Systems and Lumbar Drainage (LD) Systems are the two categories of external drainage systems. Most accessories comprise connectors, siphon controls, flow-regulating devices, and other items. It helps adjust the valves' operations and customizes shunts to meet the needs of the patients. This market's expansion is owing to the vast range of CSF-related disorders it can detect.
A shunt is a hollow tube occasionally surgically implanted in the spine or the brain. It is beneficial to drain cerebrospinal fluid (CSF) and direct it to another area of the body where it can be reabsorbed. The market offers a variety of shunt devices, including the ventriculoperitoneal (VP), ventriculoatrial (VA), lumbar peritoneal (LP), and ventriculopleural (VP) types (VPL). A valve is installed in the tubing system to ensure that the CSF flow rate through the shunt is controlled. The pressure difference between the proximal catheter tip and the drainage end is known as the change in differential pressure (DP), and it governs how most valves function.
Based on age group, the global cerebrospinal fluid management devices market is bifurcated into pediatric, adult, and geriatric.
The pediatric segment is the major contributor to the market and is estimated to grow at a CAGR of 5.40% during the forecast period. The Hydrocephalus Association estimates that one in 500 children worldwide suffer from hydrocephalus, and one to two out of every 1,000 babies are born. Over 200,000 infants worldwide are predicted to develop congenital hydrocephalus as a result of this every year. In the end, this is causing a rise in pediatric shunt surgeries. In addition, some of the industry's major firms are creating brand-new cerebrospinal fluid management devices made explicitly for treating children with hydrocephalus. These elements are anticipated to fuel this segment's expansion.
Pediatric and elderly populations have higher rates of hydrocephalus than other populations. However, grownups are also experiencing it more frequently. Hydrocephalus ex vacuo and normal pressure hydrocephalus are two different types of hydrocephalus that can affect adults. Adults with undiagnosed and untreated hydrocephalus also lose their ability to work, which raises healthcare costs. The need for cerebrospinal fluid management devices in adults is being driven by this, fueling the global market expansion for these devices.
Based on the end-use industry, the global cerebrospinal fluid management devices market is bifurcated into hospitals, ambulatory settings, and research and academic institutes.
The hospital segment is the major contributor to the market and is estimated to grow at a CAGR of 5.65% during the forecast period. Due to their simplicity, affordability, excellent safety, and effectiveness, cerebrospinal fluid management devices are becoming popular among neurosurgeons. Hospitals benefit from increased patient visits to general and specialist neurological facilities. Furthermore, most shunting operations are performed in hospitals and specialist clinics, propelling the market for cerebrospinal fluid management devices to expand. Additionally, there is a rise in the number of hospitals worldwide. Elements, including the increase in hospitals and clinics and the speedy adoption of cutting-edge technologies by specialty centers, are fueling the expansion of this market worldwide.
Medical care institutions that offer outpatient services are called ambulatory settings (surgical clinics). The provision of surgeries, minimally invasive therapies, and other procedures are all examples of services that can be included in outpatient care. Ambulatory surgical centers also increase the security of care transitions and set up patient safety and methods for clinicians and other medical professionals to improve performance and keep workflow, fueling this market's expansion.
Due to these institutes' relatively lower adoption of CSF management devices, this category is anticipated to experience moderate market growth during forecasting. The class is expected to grow during the forecast period due to expanding academic institute collaborations and an increase in global studies on diagnosing and treating neurological illnesses, including hydrocephalus.
North America Dominates the Global Market
The global cerebrospinal fluid management devices market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the major revenue contributor and is expected to grow at a CAGR of 5.70% during the forecast period. The market for cerebrospinal fluid management devices in the Americas is divided into North America and Latin America. North America is divided into the US and Canada, two powerful nations. The Americas now dominate the global market for cerebrospinal fluid management devices due to the region's abundance of medical device producers, thriving healthcare sector, and high acceptance rate among medical professionals. Many small and medium-sized businesses have entered this sector aggressively by working on creating shunts and valves to treat hydrocephalus.
Europe is expected to grow at a CAGR of 6.10% during the forecast period. Western and Eastern Europe account for most of Europe's cerebrospinal fluid management device market. Western Europe consists of Germany, France, the United Kingdom, Italy, Spain, and the remainder of the continent. Prominent manufacturers, the expansion of the biopharmaceutical industry, government funding of R&D, a high disposable income, and the availability of cutting-edge technology are significant factors driving the market's growth. Some market participants cultivate relationships with vascular and neurosurgeons to gain a competitive advantage.
In Asia-Pacific, the market for devices to regulate cerebrospinal fluid is expanding most quickly. Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific comprise the Asia-Pacific market. Increased healthcare spending, research, awareness of prominent companies, and research funding are vital drivers impacting the market's growth. For instance, the Hydrocephalus Support Association (HSA), a non-profit organization headquartered in Australia, assists people with hydrocephalus and their families in overcoming obstacles, enhancing their capacities, and leading independent lives.
The two central regions of the Middle East and Africa are the Middle East and Africa. The Middle East and Africa comprise a minor portion of the global healthcare contract manufacturing market. However, the Gulf Cooperation Council (GCC) businesses are going through a self-expansion phase and preparing to solidify their position. The expansion of multinational corporations in the region, rising R&D spending, and growing medical sector development in Middle Eastern nations are all factors driving the market's growth. A surge in partnerships between medical technology manufacturers and the region's top doctors and hospitals is also caused by the rising favorability and legal requirements in nations like Saudi Arabia.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|